Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think for stocks like ISCO with low outside ownership and volume that technical theories and charts are basically meaningless. ISCO will fly or die based on either significant progress or significant crises. Not whether one officer is the child of another, nor if the charts show a cup and handle, or some other signal. Technical analysis is likely most useful for larger stocks on larger boards with volumes where statistics and market psychologies can coincide at times. If over the next year or so, life changing efficacy is demonstrated by their technology and products, that is what could make a typically low volume stock fly super high. In the meantime, if they can grow their revenue generating units, then the company should slowly become stronger and more noticed. A PE of 40 is not unrealistically high for a small slowly growing company. If we assumed the total effective outstanding share quantity is 30 million shares, and the company stopped all research and focused only on their revenue generating units that had 1.4 million in earnings, a PE of 40 would be associated with a stock price of about $1.87/share.
Well, since some will say OUCH the end is coming when the stock falls 4 cents, I can justify saying SWEET, ISCO is UP 2.86% today versus the overall market at only up 0.01%.......Launch sequence start...Take-off time!
Fair is fair I guess!
I am hoping that the good news break point will be before there is a 30 million outstanding share point considering existing, preferred and warrants. I hope they release a positive report soon on the latest evaluations. However, it is a little unrealistic to expect that soon on the latest higher dosage transplantations. I am extremely glad they made it to phase I and II human trials. The primate studies where significant and through extremely reputable entities. They showed positive efficacy, but there is nothing like being able to talk to a patient and discuss exactly how they are feeling.
Again, best of luck everywhere.
Wishing you the best of good buys,
HS
Yes I think ISCO has potential. Even though I am down significantly and may not recoup my initial investment in ISCO, I still think it has the potential. But always beware though and truly acknowledge your risk. It is possible that you could lose most of your investment. But that is the case with almost any stock, some just more potential than others. It is possible your shares could drop to well under a dollar, maybe even as low as 10 cents if the Parkinsons trails do not prove out and other things stall and major dilution is enacted. That would not necessarily mean it would be time to load up. On the Parkinson clinical trials, I am hoping that the off time decreases more significantly and that sustained improvement is noted without levodopa medication. If we see that, ISCO could be off to the races. Also it is possible that their technology many actually prove better for traumatic brain injury. That too could push the news into the realm of the highly noticed and impactful on the stock price, allowing for much easier funding of work with minimal dilution. I still think there is likely a minimum of 2 more years before we can more definitively say or know how things are going. During that period I would expect some further dilution. I hope the subsidiary groups continue to grow and begin to fund more of the work to off-set funding needs that result in dilution. I like that they are growing, but they are not growing super fast. Still, that is better than collapsing. Under the current share structure, without a reverse split, I could easily see this hitting a 50 million outstanding share quantity before they reach the eureka point. I wish I had a crystal ball or a magic lamp, but alas, I am not that fortunate. Best of luck and invest only what you are willing to lose. Actually do yourself a mental favor and consider it gone. If it comes back in multitudes, so be it and rejoice!
This stock is so far under most radars that news really does not have the reach and thus the impact that it should.
The biggest problems with this stock IMO is:
-they always have low cash on hand.
-the cash burn rate is high (not super high), but still forces negative cash flow.
-due to the above the need for the owners to keep buying stock to fund the extra cash needs, and leads to the potential for significant dilution.
-the board they are on, placement and news reach keeps both good news somewhat hidden from the majority of potential investors.
The biggest pluses IMO are:
-They have real technology that is not a scam and has significant potential in areas of critical medical needs.
-They have accomplished most of what they say they are going to do.
-They have used their developments to support their technology to produce viable products.
-They have real earnings from the marketing branches of their products in cell technology and skin care as separate entities.
-due to the above, they are one of the few developmental/clinical stage biotech companies that have any revenue generating arm at all. Thus some of their cash burn is funded through division earnings and they additionally gain valuable marketing experience and contacts.
-They have a multitude of patents, some more valuable than others. Patents are costly to get and maintain, but add to a companies intellectual property value and can be the key to future success or buyout value.
-their clinical stage I and II studies are done through a world renowned neurological research facility. (no company that has scam technology would be able to get their foot in the door with such reputable organizations)
I don't know if any of this helps, but that is my take on ISCO.
Oh yes I have. I might be off by a few million, but fairly close. Even if it was 40 million outstanding, it only effects the share price, not the capitalization value. Do I care about the share price, of course. But I care more that the company is a success for those suffering from such debilitating diseases and conditions they seek to alleviate. A company that has safely intracranially transplanted neural stem cells they created is not a scam. Yes they may fail in the long run, but not because they are a scam.
Of course they have and you know it. This is just another example of you disingenuous misinformation campaign.
The extension study to monitor and evaluate patients every 6 months for 5 years is critical. I am glad they noted this. A 1 or 2 year evaluation is insufficient. I still do not understand the market cap for this company. There are many many many more small developmental companies out there that have less potential that are at least in the 40 to 80 million dollar capitalization range. ISCO is beyond simply developmental with profitable subsidiaries generating usable cash and clinical stage progress. Comparatively, it is my opinion this should be at least a 100 million cap at the moment and even with say an 20 million outstanding share potential, that is over $5/share. I would like to see the information on the latest efficacy report. They need to see improvement during the 'off' periods.
I think the sleazy Russian promoters have been busy elsewhere these days!
I find nothing sleazy about successful intracranial transplantation of neural cells at the Florey Institute. That is about as far from sleazy as it gets....
That is about what I hoped for. Indications of efficacy at minimal dose levels. All patients so far, 'feel better'. That fact alone makes any monies lost here to date worthwhile. Why this company is still at such low valuation surprises me. I recognize the cash situation, the backroom outstanding shares, and other issues, but when I see a company with such a product potential this far along that also has experience at and revenue from actual product production and delivery in related areas; I would really think the value of this company should be at least 500 million today. If I assume a future diluted total outstanding share value 50 million shares; that is at least $10/share. But that is today, after PD program and TBI, it should multiples of that. A cap of only 50 million with the listed O/S is over $12/share.
Bottom line, regardless of your take or investment direction in ISCO, IMHO, I think you should want this to work out well for the sake of peoples lives.
I hope the company posts the paper or transcript of the presentation. I can not get to Washington this weekend, I would have loved to attend the conference.
I have also recently asked the Micheal J Fox foundation if they have been aware of the work at Florey. I never got all the details on the efficacy shown in the primate studies with Duke. I am thrilled with the human trials because with humans, you can get patient feedback in a much more detailed manner.
Six months is still early, but if the lower dose initial safety study levels show some notable efficacy in this 6 month milestone, then they really have something going forward that could truly help people.
Best of luck to all. I know investors want to make money here, but the biggest reward would be the improvement in and longevity of the patients lives............
HS
Six Month Evaluation
Hopefully some efficacy will be notable in early results of lowest doses. We will see. At least they are getting things done.
https://www.otcmarkets.com/stock/ISCO/news/International-Stem-Cell-Corporation-to-Present-Six-Month-Results-of-Neural-Stem-Cell-Transplantation-for-Parkinson-s-Disease-at-Neuroscience-2017?id=174616&b=y
I think a market cap of 200 million is actually low for what this will be worth if a platform for treating Parkinsons and TBI is seen to be forthcoming. Lets say that we double the fully diluted share count to 36.4 million.. That would be about $5.50 per share. If they can build more of their revenue producing activities, that also would help. If we go to extended phases and have notable results, this should easily be a 700 million share cap value. Lets say by then there are 50 million shares. That is a $14 per share. If things don't falter along the way, which I must assume they can, I think we shall at least see that within the next 1 to 2 years.
Just my ignorant humble opinion.
HS
Stock symbol MRIC is about as far as I got so far. Will look closer. The 18 or so million shares at current dilution state seems about right also. If they get to phase III with good results, this could go as approach 100 a share, but I would assume more needed dilution by then.
Is there a call in number...if so at what time??
Can Ogsynian move SNMN to new highs? Time will tell. Naughty donuts has its issues. If they clean their donuts a little more they might survive. What is the progress on Funky Biscuits. Could see some climb, but not too sure on this end how good it is to enter the cannabis arena. Hopefully Ogsynian will truly move SNMN solidly upward.
3D Printing of liver tissue.....interesting...very interesting...
I can not seem to find a clear indication of what the company is based on releases. Is it Branchpoint? If so, I think they are private.
Do they have any buyers of the equity offered?
I would think it would only raise the first million. Wouldn't anymore require a penny a share or more? Am I missing something?
Ok thanks.
Agreed that previous release indicated 'Non-Dilutive'.
Oh well, if the funds are wisely spent in revenue generating entities with truly positive cash flow, then all will be OK. But that is a lot to ask at times, especially these days.
Thanks again for the feedback....
HS
Can Someone tell me what happened?
Did they offer a billion shares to someone for 0.001? I don't see any actual filings. Can anyone tell me briefly or point me to a correct indication of the share structure now and pending?
Looks like old holder sell of day.
Could be good for more true movement forward to transfuse old blood to new.
Best of luck to all.
HS
Nice to see the indications of good stewardship!
Organizing a lower share structure where possible
Focusing on revenue generation.
Cash flow is paramount.
Nice to see.
Good QA too...............
Agreed, and while it is not enough to cover all costs, they are not pre-revenue. They do have their 'functional high margin business' as well.
I said it before and will say it again; "this company has a little too high of cash burn and stays precariously low on cash, BUT they seem to near always do what it is they say they are going to do". I am sorry to the infinite naysayers if that give me some confidence, but it does. Can I guarantee success.....of course not!!!...do I think we will see some more action here, I think so........
The 2 years is a positive and negative. It means that it takes a while for this therapy to fulfill itself. I doubt there will be immediate improvement, but as the new cells survive and slowly begin to produce more dopamine the patients should see some return to normal function.
Lets hope so. I have lost a lot on this company by investing very early. Yet every cent lost will be worth it if this gives noticeable improvement in the lives of people suffering with this disease.
I think you could see some preliminary indications before the first 12 months are up. But final results and future prognosis of the patients will not be possible to report for some time (thus the 2 year honest assessment from the company).
Wishing the best for the patients first and for my portfolio second.
Also, wishing all the best of good buys!
HS
I am not so sure about that. I have been invested here for a long time and have endured extreme dilution. I am not sure I will ever get my original investment back. HOWEVER...... To me it looks more like the principle is buying just enough new stock to keep things funded on an as needed basis, in lieu of getting involved with too many costly stock offerings that usually bring the true significant dilution (which I have experienced here).
This company, while precariously operating on thin finances has done almost everything they said they would do over the many years I have been invested.
The second patient is due to undergo surgery soon. Reference:
http://www.adelaidenow.com.au/lifestyle/health/adelaide-businessman-kevin-weeks-to-be-treated-with-dopamineproducing-stem-cells-in-a-worldfirst-medical-trial-for-parkinsons-disease/news-story/187d060ba1a6945779afcae923ea3653
Best regards and wishing all the best of good buys.
HS
Should this not be a Babcock and Wilcox (BW) Message Board?
Here we go! Phase I has begun!
Today's announcement is great news, not just for ISCO investors, but for humankind in general (Especially those with Parkinsons)
Human trials are under way now! A group of patients will hopefully be able to report through clinical data and also human language concerning their cognitive improvements.
Lets hope for great results, not for us as investors, but for them as patients in need.
HS
Another slice of Polypeptide cake with mint frosting please.
There is a horizon event coming.
NNVC back to 6, then 9.
This argument about Seymour is starting to sound like 3rd grade, or should I say like three of the four republican candidates.
It should be terminated for something real.
I will get my polypeptide cake with mint frosting, and see what they have to say.
Check the Roche 10K also, you just might find something interesting.
I have said often, NNVC is not perfect or close to it, but they are not simply out to fleece the investor as is, at times, suggested.
If I was more heavily invested and had more time, I would go down and meet with them. I would love to check out the facility myself. I would love to speak with Seymour and Boniuk.
I think Dr. Boniuk has influenced the direction of the company recently. While I have also been critical of distractions they have chased, the one I believe Dr Boniuk is pushing might just be the key to NNVCs future progress. I think the topicals and eye products will be much easier to bring to market. If they could do that, they could fund themselves fully to achieve an amazing position in providing advanced nanotheraputics to humankind.
HS
Thanks for the detailed unbiased reply.
No company executes perfectly or is perfect in their press releases. I often laugh when some people talk about how inefficient the government is. I have worked in industry and have interfaced with government on certain projects. I have found private industry to be a very inefficient, even more so than the government at many times. If you look at the total lifetime expenditure by NNVC to develop what they have with the verified efficacy to date, it is more efficient that the average for sure. Timelines have slipped often, which is a disappointment, but is it more important to obtain results per dollar invested. NNVC is probably not the highest efficiency in that regard amoungst all other possible comparatives, but they rank up there for sure. My biggest worry has been the timeline slips and the potential for competition to take advantage of that.
Best of luck to all NNVC longs.
HS
Perhaps, and I think that is so at times. But I suspect is it also often more of either an ulterior motive or a need to find something which one can be negative about.
I would have to go back and read those transcripts before I could concur. Yet, the tox situation does not correlate to a fraudulent science in any manner. It only translates to the problem most developmental biotech companies have in trying to prearrange all the necessary crap and non-crap the FDA demands of them.
First of all, that is very atypical. Secondly, so you suspect these laboratory entities are falsifying, fraudulent liars. It is amazing how negative that is. If you truly believe that, you should leave and go toward something that you do believe in. Life is too short to hang around something you hate or think is fraudulent.
Successful independent laboratory results are far more valid and important than any peer review or referee of some paper.
Independent laboratory results are real and actual and have nothing to do with faith. You may choose to ignore them, but real and actual they remain.
HS
Considering NNVC could be awarded for the best of all new therapeutics in realm of world pharma, one might be suspicious. Yet suspicion is often based on a recognition of greatness in something when there is a lack of understanding. It has been well documented that NNVC’s science is valid and effective in nearly all aspects tested to date. The challenge is to navigate the rather insane pharmaceutical product development landscape the US FDA imposes on the scientific community regarding therapeutics. Having said that, it is also not unusual for other opposing forces to make themselves known simply to generate as much havoc and doubt as is possible just for the fun of it. That, sadly, has become the American Way.
Nietzsche was one of the world’s greatest pessimists. Regarding NNVC or any other company with good, or bad, technology would have never even tried if they followed Nietzsche who strongly felt there was no point in anything.
Look to Leibniz, Pope, Russell for reasons NNVC began and just might prosper eventually.
“A pessimist sees the difficulty in every opportunity; an optimist sees the opportunity in every difficulty.” - Winston S. Churchill
Go NNVC, keep on Truckin!
I am not sure what you are responding to. Something is mysteriously missing here. Is there something illegal about short positioning on NNVC?